Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle
Open Access

Compensatory Expression of Nur77 and Nurr1 Regulates NF-κB–Dependent Inflammatory Signaling in Astrocytes

Katriana A. Popichak, Sean L. Hammond, Julie A. Moreno, Maryam F. Afzali, Donald S. Backos, Richard D. Slayden, Stephen Safe and Ronald B. Tjalkens
Molecular Pharmacology October 2018, 94 (4) 1174-1186; DOI: https://doi.org/10.1124/mol.118.112631
Katriana A. Popichak
Departments of Environmental and Radiological Health Sciences (K.A.P., S.L.H., R.B.T.) and Microbiology, Immunology and Pathology (J.A.M., M.F.A., R.D.S.), College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado; Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (D.S.B.); and Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas (S.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean L. Hammond
Departments of Environmental and Radiological Health Sciences (K.A.P., S.L.H., R.B.T.) and Microbiology, Immunology and Pathology (J.A.M., M.F.A., R.D.S.), College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado; Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (D.S.B.); and Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas (S.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie A. Moreno
Departments of Environmental and Radiological Health Sciences (K.A.P., S.L.H., R.B.T.) and Microbiology, Immunology and Pathology (J.A.M., M.F.A., R.D.S.), College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado; Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (D.S.B.); and Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas (S.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maryam F. Afzali
Departments of Environmental and Radiological Health Sciences (K.A.P., S.L.H., R.B.T.) and Microbiology, Immunology and Pathology (J.A.M., M.F.A., R.D.S.), College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado; Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (D.S.B.); and Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas (S.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald S. Backos
Departments of Environmental and Radiological Health Sciences (K.A.P., S.L.H., R.B.T.) and Microbiology, Immunology and Pathology (J.A.M., M.F.A., R.D.S.), College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado; Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (D.S.B.); and Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas (S.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard D. Slayden
Departments of Environmental and Radiological Health Sciences (K.A.P., S.L.H., R.B.T.) and Microbiology, Immunology and Pathology (J.A.M., M.F.A., R.D.S.), College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado; Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (D.S.B.); and Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas (S.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Safe
Departments of Environmental and Radiological Health Sciences (K.A.P., S.L.H., R.B.T.) and Microbiology, Immunology and Pathology (J.A.M., M.F.A., R.D.S.), College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado; Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (D.S.B.); and Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas (S.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald B. Tjalkens
Departments of Environmental and Radiological Health Sciences (K.A.P., S.L.H., R.B.T.) and Microbiology, Immunology and Pathology (J.A.M., M.F.A., R.D.S.), College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado; Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado (D.S.B.); and Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas (S.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    C-DIM5 alone and MPTP/IFNγ/TNFα-induced mRNA expression in primary mixed glia over 24 hours. (A) Flow cytometry scatter plots show the percentage of Cd11b (microglia, 12%) or GLAST-positive (astrocytes, 78.8%) cells in mixed glial cultures. (B) C-DIM5 alone increases Nur77 mRNA at 4 hours and MPTP/IFNγ/TNFα mildly activates Nur77; both synergistically show an increase. (C) C-DIM5 alone does not increase Nurr1. (D) Time course over 24 hours demonstrates the most inflammatory gene expression at 4 hours, whereas C-DIM5 does not. (E) C-DIM5 suppresses inflammatory gene expression at 4 hours. Data depicted as ±S.E.M. (n = 3–14); mRNA fold change; internal control (β-actin or HPRT). Statistical significance shown as mean compared with control except for those depicted in 2E, where statistical significance is compared with MPTP/TNF/IFN. *P < 0.05; **P < 0.01; ****P < 0.0001.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    C-DIM5 inhibits NF-κB activity in HEK NF-κB-GFP/luciferase reporter cells upon hNR4A1-FLAG (Nur77) overexpression through a nuclear specific mechanism exhibited in primary astrocytes. (A) Western blot and representative images demonstrating increased (arrows) Nur77 and FLAG in HEK dual-reporter cells. (B) Representative images demonstrating increased nuclear Nur77 upon overexpression in the presence of C-DIM5 after TNF treatment in HEK cells. (C and D) Quantitative graphs demonstrate decreased NF-κB activity via luciferase and GFP expression. (E) A time-course graph demonstrating increased nuclear p65 expression under the influence of MPTP and IFNγ/TNFα at 30 minutes in primary astrocytes. Additionally, C-DIM5 does not suppress p65 translocation. (F) Representative images of p65 translocation in astrocytes under basal conditions and/or stimulation with MPTP (10 μM) and TNF-α (10 pg/μl)/IFN-γ (1 ng/μl) in the absence or presence of 1 μM C-DIM5. Data depicted as ±S.E.M *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 n = 100–200 cells per group from three biologic replicates across three independent experiments.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    C-DIM5 prevents Nur77 (NR4A1) from translocating to the cytoplasm and shuttles Nurr1 (NR4A2) to the nucleus under inflammatory stimuli. (A) Representative images of Nur77 translocation in astrocytes under control (saline) conditions and/or stimulation with MPTP/IFNγ/TNFα in the absence or presence of C-DIM5. (B) A quantitative figure demonstrating nuclear Nur77 expression at time point 30 minutes upon inflammatory stimuli and/or C-DIM5 treatment. (C) Representative images of Nurr1 translocation in astrocytes under control (saline) conditions and/or stimulation with MPTP/IFNγ/TNFα in the absence or presence of C-DIM5. (D) A quantitative figure demonstrating nuclear Nurr1 expression at time point 30 minutes upon inflammatory stimuli and/or C-DIM5 treatment or DMSO-vehicle control treatment. Data depicted as ±S.E.M *P < 0.05; **P < 0.01; ****P < 0.0001 n = 100–200 cells per image field per group for n = 3 across three independent experiments.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    RNAi targeted toward Nur77 and Nurr1 effectively knocks down Nur77 and Nurr1 mRNA expression in primary pure astrocytes, respectively. (A) Nur77 is silenced alone at 48 hours, which selectively increases expression of NR4A2/Nurr1 without affecting expression of NR4A3/NOR1. (B) Nurr1 is silenced alone, which selectively increases expression of NR4A1/Nur77 without affecting expression of NR4A3/NOR1 (C) Double knockdown of both Nur77 and Nurr1 effectively suppresses Nur77 and Nurr1, respectively. (D) Transfecting primary mixed glia effectively removes microglia yielding pure GLAST-positive primary astrocytes, as demonstrated by flow cytometry. (E) Twenty-four hour treatment with C-DIM5 alone or with MPTP-cytokines shows increased Nur77 protein compared with less Nurr1 protein. C-DIM5 effectively increases Nur77 at 24 hours versus 8 hours, whereas Nurr1 expression is expressed more at 8 hours. (F) Double knockdown prevents Nos2, Il1β, Il6, and Tnfα suppression by C-DIM5 with MPTP-cytokines. Data depicted as ±S.E.M. (n = 4–22/group); mRNA fold change; internal control (β-actin or HPRT). Statistical significance shown as mean compared with control. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    ChIP-seq analysis of p65-bound genes in C-DIM5-treated MPTP-exposed astrocytes. C-DIM5 largely restores NF-κB-mediated inflammatory and apoptosis gene expression back to control levels as measured by a qPCR array study. (A) Venn diagram depicting unique and overlapping genes bound to p65 in C-DIM5 and vehicle (DMSO)-treated MPTP exposed astrocytes. (B) Bar plot for the gene ontology analysis of biologic processes found to be statistically unique in the C-DIM5-treated MPT-exposed astrocytes. –log(P value) used to rank the degree of enrichment of the top 21 genes. The number next to each bar represents the number of associated genes corresponding to C-DIM5–treated MPTP-exposed astrocytes. (C) Genome browser view of distribution of the ChIP-seq reads of represented genes in both C-DIM5- and DMSO-treated MPTP-exposed astrocytes. (D) A cluster gram and heat map demonstrate gene pattern expression similarities among treatment groups, MPTP/IFNγ/TNFα + C-DIM5 clusters with control (saline) levels; MPTP/IFNγ/TNFα clusters alone. (E) MPTP/IFNγ/TNFα increases gene expression from control, whereas C-DIM5 decreases MPTP/IFNγ/TNFα -induced gene expression. MPTP/IFNγ/TNFα + C-DIM5 has minimal changes in gene expression compared with control. (n = 4/group in array studies).

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Small molecule docking of C-DIM5. (A) Predicted binding orientation of C-DIM5 (shown in yellow) at the ligand-binding site of NR4A1 (shown in purple). (B) Inset depicts the specific residues of the calculated binding site in NR4A1 (gray) and their predicted interactions with C-DIM5 as dashed lines (pink=hydrophobic/π-alkyl, purple=π-σ, cyan=π-cation/π-anion, and green=hydrogen bonds). (C) Bond types shown for predicted binding interactions between C-DIM5 and NR4A1. (D) Predicted binding orientation of C-DIM5 (shown in yellow) at the coactivator-binding site of NR4A2 (shown in blue). (E) Inset depicts the specific residues of the calculated binding site in NR4A2 (gray) and their predicted interactions with C-DIM5, with (D) bond types shown for predicted binding interactions between C-DIM5 and NR4A2.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

     Primer table.

    Primer sequences of measured genes in qPCR experiments separate from the SABiosciences NF-κB-targeted gene array.

    GeneAccession No.Primer Sequence (5′-3′)Length
    NOS2NM_010927.3For: TCA CGC TTG GGT CTT GTTbp
    Rev: CAG GTC ACT TTG GTA GGA TTT149
    TNFαNM_013693.3For: CTT GCC TGA TTC TTG CTT CTG140
    Rev: GCC ACC ACT TGC TCC TAC
    IL-1βNM_008361.3For: GCA GCA GCA CAT CAA CAA G90
    Rev: CAC GGG AAA GAC ACA GGT AG
    NURR1/NR4A2NM_001139509.1For: GTG TTC AGG CGC AGT ATG G153
    Rev: TGG CAG TAA TTT CAG TGT TGG T
    CCL2NM_011331.2For: TTAAAAACCTGGATCGGAACCAA121
    Rev: GCATTAGCTTCAGATTTACGGGT
    CCL5NM_013653.3For: GCT GCT TTG CCT ACC TCT CC104
    Rev: TCG AGT GAC AAA CAC GAC TGC
    IL-6NM_031168.1For:CTG CAA GAG ACT TCC ATC CAG131
    Rev:AGT GGT ATA GAC AGG TCT GTT GG
    β-ACTINNM_007393.3For: GCT GTG CTA TGT TGC TCT AG117
    Rev: CGC TCG TTG CCA ATA GTG
    HPRTNM_013556.2For: TCA GTC AAC GGG GGA CAT AAA142
    Rev: GGG GCT GTA CTG CTT AAC CAG
    NOR1/NR4A3XM_006537657.3For: TGC GTG CAA GCC CAG TAT AG60
    Rev: ATA AGT CTG CGT GGC GTA AGT
    NUR77/NR4A1NM_010444.2For: TTG GGG GAG TGT GCT AGA AG202
    Rev: GTA GGC TTG CCG AAC TCA AG
    • View popup
    TABLE 2

     Reduction in secreted cytokines by C-DIM5

    Inflammatory cytokines secreted upon MPTP/IFNγ/TNFα treatment are significantly reduced upon addition of C-DIM5.

    GroupSecreted Cytokine Concentration (pg/ml)TARC
    IL2IL6IL-12p70CCL2MIP-1aCCL5
    Control—1.9 ± 0.65*-**13.2 ± 0.67**-*5.7 ± 0.52**9.6 ± 0.47*
    MPTP/TNF/IFN3.1 ± 0.2484.6 ± 1.137.4 ± 0.33750.4 ± 7.584.1 ± 1.091916 ± 153.5518.4 ± 0.80
    MPTP/TNF/IFN + C-DIM52.6 ± 0.1555.1 ± 2.53**2.4 ± 0.27**279.5 ± 5.74**—*111.2 ± 3.08**16.6 ± 1.46*
    • —, Result lower than limit of detection.

    • ↵* P < 0.01; **P < 0.001 Statistical significance from MPTP/TNF/IFN group (n = 4/group).

Additional Files

  • Figures
  • Tables
  • Data Supplement

    • Supplement Figure 1 - PDB -

      Crystal structure coordinates. Protein data bank file for the crystal structure coordinates for the NR4A1 ligand binding domains (PDB ID: 1YJE) (Data Supplement Figure 1) downloaded from the protein data bank (pdb format) used to assist in predicted binding orientation of C-DIM5.

    • Supplemental Figure 2 - PDB -

      Crystal structure coordinates. Protein data bank file for the crystal structure coordinates for the NR4A2 ligand-binding domain (PDB ID: 1OVL) (Data Supplement Figure 2) downloaded from the protein data bank (pdb format) used to assist in predicted binding orientation of C-DIM5.

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 94 (4)
Molecular Pharmacology
Vol. 94, Issue 4
1 Oct 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Compensatory Expression of Nur77 and Nurr1 Regulates NF-κB–Dependent Inflammatory Signaling in Astrocytes
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

NR4A Receptors Modulate NF-κB Inflammatory Signaling in Glia

Katriana A. Popichak, Sean L. Hammond, Julie A. Moreno, Maryam F. Afzali, Donald S. Backos, Richard D. Slayden, Stephen Safe and Ronald B. Tjalkens
Molecular Pharmacology October 1, 2018, 94 (4) 1174-1186; DOI: https://doi.org/10.1124/mol.118.112631

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

NR4A Receptors Modulate NF-κB Inflammatory Signaling in Glia

Katriana A. Popichak, Sean L. Hammond, Julie A. Moreno, Maryam F. Afzali, Donald S. Backos, Richard D. Slayden, Stephen Safe and Ronald B. Tjalkens
Molecular Pharmacology October 1, 2018, 94 (4) 1174-1186; DOI: https://doi.org/10.1124/mol.118.112631
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics